Candriam S.C.A. Increases Stock Position in Edwards Lifesciences Corporation $EW

Candriam S.C.A. grew its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 3.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 58,485 shares of the medical research company’s stock after purchasing an additional 1,838 shares during the quarter. Candriam S.C.A.’s holdings in Edwards Lifesciences were worth $4,574,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Rosenberg Matthew Hamilton acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $28,000. Quantbot Technologies LP purchased a new stake in Edwards Lifesciences in the first quarter valued at approximately $26,000. NewSquare Capital LLC boosted its holdings in shares of Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the period. SouthState Corp purchased a new position in shares of Edwards Lifesciences during the first quarter worth approximately $27,000. Finally, Costello Asset Management INC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $29,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 22,970 shares of company stock worth $1,862,878. Company insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a research note on Monday, November 3rd. Piper Sandler reiterated an “overweight” rating and set a $95.00 target price (up previously from $90.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. William Blair upgraded Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Jefferies Financial Group set a $98.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Robert W. Baird set a $83.00 target price on Edwards Lifesciences in a research note on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.39.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $86.35 on Friday. The company has a market cap of $50.11 billion, a P/E ratio of 12.42, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. Edwards Lifesciences Corporation has a one year low of $65.31 and a one year high of $87.21. The business has a fifty day moving average of $78.20 and a two-hundred day moving average of $77.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm posted $0.67 EPS. The business’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.